CFP and neoplasm: NCRs participate in tumour cells recognition by binding ligands such as tumour cell-derived HLA-B-Associated transcript 3 (BAT3), B7-H6, mixed-lineage leukaemia protein-5, or properdin, respectively, expressed either intracellularly, extracellularly, or released as a soluble ligand [101,102,103,104].